Heron Therapeutics saw no growth in patent filings and highest growth of 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Heron Therapeutics’s patent filings and grants. Buy the databook here.
Heron Therapeutics has been focused on protecting inventions in United States(US) with three publications in Q2 2024
The United States(US) Patent Office dominates the patent filings with nearly 100% of filings. The United States(US), and European Patent Office(EPO) patent Office are among the top ten patent offices where Heron Therapeutics is filings its patents. Among the top granted patent authorities, Heron Therapeutics has 100% of its grants in European Patent Office(EPO).
Roche and Johnson & Johnson could be the strongest competitors for Heron Therapeutics
Patents related to data science and machine learning lead Heron Therapeutics's portfolio
Heron Therapeutics has the highest number of patents in data science followed by, machine learning and digitalization. For data science, nearly 29% of patents were filed and no patents were granted in Q2 2024.
Emesis (vomiting) related patents lead Heron Therapeutics portfolio followed by nausea, and autonomous driving
Heron Therapeutics has highest number of patents in emesis (vomiting) followed by nausea, autonomous driving, mos micro (mpu, mcu & dsp), and machine learning.
For comprehensive analysis of Heron Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.